secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001048477-24-000149
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q3 revenue $746M (+28% YoY), GAAP EPS $0.55 (+162%), raises FY2024 guidance
--------------------------------------------------------------------------------

- Total revenues $746M (+28% YoY); VOXZOGO revenue +54% YoY; enzyme therapies +27%.
- GAAP diluted EPS $0.55 (+162%); Non-GAAP diluted EPS $0.91 (+98%).
- Raised full-year 2024 guidance for total revenue, Non-GAAP operating margin, and Non-GAAP EPS.
- Retired $495M convertible debt in cash, eliminating ~4M dilutive shares.
- Over 3,800 children on VOXZOGO; majority of US new starts under age 5.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/0001048477-24-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847724000149/bmrn-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001048477-24-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer